Skip to main content
SpringerLink
Log in

Use of Zafirlucast, Cysteine-Containing Leukotriene Antagonist, in Epinephrine-Induced Heart Injury

  • Published:
Bulletin of Experimental Biology and Medicine Aims and scope

Abstract

Combination of preventive and repeated (after 12 h) injections of zafirlucast in a daily dose of 40 mg/kg to animals with epinephrine-induced heart injury essentially decreased the content of leukotriene C4, but did not prevent the increase of leukotriene B4 content in the blood, though decreased its content in comparison with the level observed 24 h after epinephrine injection by 11%. Two injections of zafirlucast had a favorable impact on serotonin content in the myocardium (this parameter decreased by 19%), promoted a decrease in epinephrine content and normalization of the norepinephrine/epinephrine ratio, did not change prostaglandin content and ratio, and slightly decreased histamine content in the myocardium. The effect of zafirlucast can be explained by a decrease of oxidative stress. Zafirlucast decreased blood content of myofibrillar fraction of creatine phosphokinase (by 22%) and slightly improved elastic characteristics of erythrocytes. These results suggest that zafirlucast can be added to combined therapy of necrotic, stress-induced, hypoxic, and ischemic injuries of the myocardium.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. S. V. Vasil'eva, V. A. Antelava, E. A. Chikobava, et al., Byull. Eksp. Biol. Med., Suppl. 2, 21–29 (2002).

    Google Scholar 

  2. M. K. Bach, J. R. Braschler, R. E. Peck, and D. R. Morton, J. Allergy Clin. Immunol., 74, 353–357 (1984).

    Google Scholar 

  3. K. Fukatsu, H. Saito, I. Han, et al., J. Surg. Res., 68, 79–86 (1997).

    Google Scholar 

  4. J. E. McGee and F. A. Fitzpatrick, Proc. Natl. Acad. Sci. USA, 83, 1349–1353 (1986).

    Google Scholar 

  5. T. M. McIntyre, G. A. Zimmerman, and S. M. Prescott, Ibid., 2204–2208.

  6. O. Radmark, T. Shimizu, H. Jornvall, and B. Samuelson, J. Biol. Chem., 259, 12,339–12,345 (1984).

    Google Scholar 

  7. S. Rosengren, J. Bjork, and G. Smedegrad, Lab. Invest., 58, 559–564 (1988).

    Google Scholar 

  8. S. Shak and I. M. Goldstein, J. Biol. Chem., 259, 10,181–10,187 (1984).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology, Tbilisi State Medical University, Russia

    N. V. Gongadze & T. D. Kezeli

  2. Republican Research Center of Medical Biophysics and Introduction of New Biomedical Technologies, Tbilisi

    N. V. Gongadze & T. D. Kezeli

Authors
  1. N. V. Gongadze
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. D. Kezeli
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gongadze, N.V., Kezeli, T.D. Use of Zafirlucast, Cysteine-Containing Leukotriene Antagonist, in Epinephrine-Induced Heart Injury. Bulletin of Experimental Biology and Medicine 134, 451–453 (2002). https://doi.org/10.1023/A:1022686129654

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1022686129654

Search

Navigation